Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation

Charlton, Michael; Gane, Edward; Manns, Michael P.; Brown, Robert S.; Curry, Michael P.; Kwo, Paul Y.; Fontana, Robert J.; Gilroy, Richard; Teperman, Lewis; Muir, Andrew J.; McHutchison, John G.; Symonds, William T.; Brainard, Diana M.; Kirby, Brian J.; Dvory‐Sobol, Hadas; Denning, Jill; Arterburn, Sarah; Samuel, Didier; Forns, Xavier; Terrault, Norah A.

doi:10.1053/j.gastro.2014.10.001

Cited by 325 publications

(306 citation statements)

References 26 publications

Supporting

Mentioning

266

Contrasting

Unclassified

Order By: Relevance

“…Charlton et al 77 have shown that SOF and RBV combination therapy for 24 weeks is an effective and welltolerated interferon-free treatment for post-transplantation HCV infection. They treated 40 patients of postliver transplant HCV with SOF and RBV for 24 weeks.…”

Section: Management Of Hcv Infection After Liver Transplant (Lt)mentioning

confidence: 99%

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Puri

Saraswat

Dhiman

et al. 2016

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

India contributes significantly to the global burden of HCV. While the nucleoside NS5B inhibitor sofosbuvir became available in the Indian market in March 2015, the other directly acting agents (DAAs), Ledipasvir and Daclatasvir, have only recently become available in the India. The introduction of these DAA in India at a relatively affordable price has led to great optimism about prospects of cure for these patients as not only will they provide higher efficacy, but combination DAAs as all-oral regimen will result in lower side effects than were seen with pegylated interferon alfa and ribavirin therapy. Availability of these newer DAAs has necessitated revision of INASL guidelines for the treatment of HCV published in 2015. Current considerations for the treatment of HCV in India include the poorer response of genotype 3, nonavailability of many of the DAAs recommended by other guidelines and the cost of therapy. The availability of combination DAA therapy has simplified therapy of HCV with decreased reliance of evaluation for monitoring viral kinetics or drug related side effects. ( J CLIN EXP HEPATOL 2016;6:119-145) T here have been revolutionary changes in the management of chronic hepatitis C (CH-C) over the last few years. Pegylated interferon alfa (Peg-IFNa) plus ribavirin (RBV) therapy, which till the recent past was the standard of care, has been eclipsed by the arrival of newer directly acting antiviral agents (DAAs). Not only do the DAAs have better efficacy, they are also associated with lower side effects, have better tolerability, a shorter duration of therapy, and have simpler administration.In the recent guidelines issued by the American Association for the study of Liver Diseases (AASLD), in collaboration with the Infectious Diseases Society of America 1 and the European Association for Study of the Liver z (EASL), 2 the role of Peg-IFNa/RBV therapy in the management of HCV has been relegated to second-line, backup status. These newer guidelines, however, cannot be implemented in India as many of the recommended drugs are yet to be marketed in India. Other considerations for the treatment of HCV in India are a predominance of

show abstract

Section: Management Of Hcv Infection After Liver Transplant (Lt)mentioning

confidence: 99%

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Puri

Saraswat

Dhiman

et al. 2016

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

show abstract

“…5 Recent literature also suggests the safe use of DAAs with or without ribavirin among liver transplant recipients, with a high sustained virologic response rates. [11][12][13][14][15] Successful clearance of HCV after an LT can reduce the risk of subsequent HCV-related complications (eg, progression to cirrhosis and graft loss). [16][17][18] It will be ideal to treat patients before LT to minimize the posttransplant HCV-related complications.…”

Section: Discussionmentioning

confidence: 99%

Untitled

Ofosu

Durand²,

Saberi³

et al. 2015

Exp Clin Transplant

View full text Add to dashboard Cite

“…However, newly developed DAAs make it easy to achieve a SVR both among compensated liver transplant recipients with no fibrosis or mild fibrosis [147,148] and before liver transplantation [149].…”

Section: Reinfection Following Liver Transplantationmentioning

confidence: 99%

APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing

et al. 2016

View full text Add to dashboard Cite

The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party on ''APASL consensus statements and recommendations for management of hepatitis C'' in March 2015 to revise the ''APASL consensus statements and management algorithms for hepatitis C virus infection'' (Hepatol Int 6:409-435, 2012). The working party consisted of expert hepatologists from the Asian-Pacific region gathered at the Istanbul Congress Center, Istanbul, Turkey on 13 March 2015. New data were presented, discussed, and debated during the course of drafting a revision. Participants of the consensus meeting assessed the quality of the cited studies. The finalized recommendations for hepatitis C prevention, epidemiology, and laboratory testing are presented in this review.

show abstract

Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation

Cited by 325 publications

References 26 publications

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Untitled

APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing

Contact Info

Product

Resources

About